SecBot SecBot

CORT

CORCEPT THERAPEUTICS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001088856 Biotech & Drug Discovery
$69.00 −3.94 (−5.41%)
Nov 16 4:00 PM ET · prev $72.94
Market cap
$8.1B
Mid cap
Consensus
Buy
83% Buy or better · 12 analysts
Median target
$164.00
+138% · range $50.00–173.00
1 year
−8.2%
from $75.12 · Nov 17
30 days
−37.4%
from $110.16
52-week range
$32.15–123.57
−44% from high · low Mar 13
Avg volume 20D
1.31M
shares / day
Short interest
9.13M
≈8.3% of shares · +6.3%
Days to cover
8.1
at average volume
Insider net
−$16.9M
0 buyers · 5 sellers · since Sep 2
New fund stakes
2
Q2 2026 13F · 1 exit
Filing reports
36
analyzed by SecBot
SecBot read MIXED 15 reports · 90 days
Balance 4 bearish · 1 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 9/15 ·Next FDA decision date, Dec 17, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $16.9M.

  • InstitutionsBULLISH

    Q2 2026: 44 added (2 new), 24 trimmed or exited. Largest new: Fuller & Thaler Asset Management, $61.7M, Jacobs Levy Equity Management $60.5M.

  • AnalystsBULLISH

    10 of 12 rate it Buy or better. Median target $164.00 (+138%).

  • Short sellersSTEADY

    Short interest +6.3% to 9.13M shares. 8.1 days to cover, ≈8.3% of shares.

  • TrendDOWNTREND

    33% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
1
exit
$122.2M
in new stakes
FundMoveSharesValue
D. E. Shaw & Co., Inc.TRIM883,001$76.8M
FULLER & THALER ASSET MANAGEMENT, INC.NEW710,106$61.7M
JACOBS LEVY EQUITY MANAGEMENT, INCNEW695,532$60.5M
Allspring Global Investments Holdings, LLCDOUBLED523,192$46.3M
NORGES BANKTRIM487,055$42.3M
Nuveen, LLCDOUBLED388,078$33.7M
BANK OF AMERICA CORP /DE/DOUBLED328,565$28.6M
JPMORGAN CHASE & COADD253,182$22.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 83% rate it Buy or better
Strong Buy3Buy7Hold1Sell0Strong Sell1
12-month targets · 5 analysts

Price is inside the target range. Median implies +138%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 4, 2026Piper Sandler
REITERATE
REITERATEOverweight
Sep 18, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 30, 2026Piper Sandler
REITERATE
REITERATEOverweight
Jul 30, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Jul 30, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 29, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$16.9M
sold · 5 insiders
DateInsiderTypeValue
Nov 10, 2026
Swisher Daniel N JR
Director
Nov 10, 2026
EXERCISE$4.2K
Nov 10, 2026
Swisher Daniel N JR
Director
Nov 10, 2026
SELL$111.1K
Nov 10, 2026
Swisher Daniel N JR
Director
Nov 10, 2026
EXERCISE$15.5K
Nov 3, 2026
Maduck Sean
Nov 3, 2026
EXERCISE$108.8K
Nov 3, 2026
Maduck Sean
Nov 3, 2026
SELL$706.8K
Nov 3, 2026
Maduck Sean
Nov 3, 2026
SELL$375.5K
Nov 2, 2026
Maduck Sean
Nov 2, 2026
SELL$964.1K
Nov 2, 2026
Maduck Sean
Nov 2, 2026
EXERCISE$97.9K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.84$0.60–$1.09-12.9%$374.2M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
9,125,717
shares short
+6.3%
vs prior settlement
8.1
days to cover
≈8.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Two insiders at Corcept Therapeutics sold shares in the week following a strong Q3 earnings report. Director Swisher…
CLUSTER · Impact 2/10
Nov 10, 2026 SEC
Director Daniel Swisher Jr. filed a Form 144 notice of intent to sell 1,500 shares of Corcept Therapeutics common…
144 · Impact 2/10
Nov 10, 2026 Insider
Swisher Daniel N JR acquired via exercise 400 shares
Director @ $10.50 ($4.2K)
Nov 10, 2026 Insider
Swisher Daniel N JR sold 1,500 shares
Director @ $74.07 ($111.1K)
Nov 10, 2026 Insider
Swisher Daniel N JR acquired via exercise 1,100 shares
Director @ $14.08 ($15.5K)
Nov 4, 2026 SEC
Two insiders at Corcept Therapeutics sold a combined $1.50M in open-market shares on November 2-3, 2026, following the…
CLUSTER · Impact 2/10
Nov 3, 2026 Earnings result
CORT Q3 2026 Earnings: EPS $1.01 (+24.7% vs est)
Jul 23, 2026 Event
Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc. et al
Court ruling (cand), Docket: 5:24-cv-03567
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

36 filings · 6 bullish · 5 bearish · 25 neutral
All CORT filing & press-release reports (36)